Write what you believe about your stocks; every morning the cited record grades it: supported, challenged, or untouched. Never opinions.

AEQUS · NSE

Aequs

₹275.05

▼ -1.59%

Close (EOD), as of 1 Oct 2026 · source

Not in active coverage. Cited reporting has mentioned Aequs, the record of those mentions is below. Your interest is logged; coverage expands by demand.

Mentions in cited reporting

The board of directors of Aequs approved the preferential issue of up to 28.07 million warrants to the Promoter Group, aggregating approximately ₹650 crore.

business-standard.comsingle-source report30 Sep 2026

Aequs plans to raise approximately ₹800 crore in debt by the end of this year, with deployment scheduled through the middle of next year.

cnbctv18.comsingle-source report28 Sep 2026

Aequs has planned a Rs 660 crore capex budget for FY27 and an upcoming Rs 800 crore debt raise.

capexmoneycontrol.comsingle-source report28 Sep 2026

Aequs' board has approved ₹650 crore equity infusion, which will be deployed to expand capacity in aerospace and consumer business besides supporting its borrowing programme.

thehindubusinessline.comsingle-source report26 Sep 2026

The Promoter Group has committed a capital infusion of approximately Rs 650 crore into Aequs through the subscription of convertible warrants.

capitalmarket.comsingle-source report26 Sep 2026

Aequs' board has approved a preferential issue of up to 2,80,71,690 warrants to Mellwood Trustee Services Private Limited for approximately ₹650 crore.

cnbctv18.comsingle-source report25 Sep 2026

Raymond, Unimech Aerospace and Manufacturing, Apollo Micro Systems and Aequs rallied up to 10 per cent during intra-day trade.

zeebiz.comsingle-source report22 Sep 2026

Every claim carries its citation

This page lists where cited reporting has mentioned Aequs. It is not the full dossier: developments here are single mentions, not corroborated records. We compile and cite; we do not opine.

New here? The reader's guide explains every page, plate by plate.

fregime is informational research software. Content on this page is factual reporting compiled from cited public sources; nothing here is advice, and nothing here expresses an opinion on any security. fregime is not registered with SEBI as an investment adviser or research analyst. Before making investment decisions, consult a SEBI-registered adviser. Price figures are delayed end-of-day values cited to the exchange's published file, never live quotes.